玻拉克斯五水合物作为一个有前途的基血管生成抑制剂
概括
玻五酸盐 (BPH) 通过抑制瘤生长和血管形成,显示出作为抗癌剂的前景. 这种化合物有效地减少了细胞增殖和血管生成,这表明了新的癌症治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 化合物正在研究用于癌症预防和治疗.
- 血管新生,新血管的形成,对于癌症的进展至关重要.
- 胰腺癌和癌是特别具有挑战性的,因为它们具有攻击性和抗化学疗法.
研究的目的:
- 为了研究玻五酸盐 (BPH) 的抗血管效应.
- 评估BPH的抗增殖和抗瘤活动.
- 探索BPH作为血管生成相关疾病的潜在治疗剂.
主要方法:
- 针对抗增殖活性进行MTT测定.
- 在试管培养和在卵子中的胆 ?? 质膜 (CAM) 测定抗血管效应.
- 针对VEGF水平的西部斑点分析和体内埃里希瘤癌 (EAC) 瘤血管生成模型.
主要成果:
- BPH 显示了对癌细胞和内皮细胞的剂量依赖的抗增殖和抗血管生成活性.
- BPH显著降低了癌细胞和瘤组织中的VEGF水平.
- 在体内,BPH治疗导致瘤大小和VEGF和TGF-β1水平的降低.
结论:
- BPH 具有显著的抗血管和抗瘤特性.
- BPH显示出作为癌症治疗的新型治疗剂的潜力.
- 针对血管生成相关疾病的进一步药物开发研究可能会从BPH中受益.
更多相关视频
09:34Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair
Published on: September 7, 2017
9.2K
09:03Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
9.7K
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Mechanism of Angiogenesis
5.1K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
100
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
100
